Your New Stock Profile Is US Lithium Corp (LITH)
Riding A Massive CB Industry Boom
February 18th, 2020 - 4 PM
Hello Member,
Dan Davis here bringing you another emerging growth company that just released news on January 21th, 2020 that it’s jumping on a massive $146 billion CBD market opportunity.
See full news release below.
It’s another potential big opportunity on a company that’s flying well under the radar of most investors. Yet, it could potentially be setting up for monster growth.
The CBD Boom Is Just Getting Started
Thanks to incessant consumer demand, legalization around the world, the global cannabis market is on course to become a $146.4 billion opportunity, according to Grand View Research.
But that may just be the start, as support only grows.
According to the Pew Research Center, 67% of Americans now support cannabis legalization with only 32% of adults now opposing its legalization.
Plus, right now, 14% of Americans are using CBD products, according to a Gallup poll.
“We project retail CBD sales will increase to $10.3 billion by 2024, a five-year compound annual growth rate of 54%,” says Kristen Nichols, editor of the 2nd Annual Hemp & CBD Industry Factbook.
No wonder major retailers are racing to keep CBD products on shelves. To date, Neiman Marcus, Sephora, Vitamin Shoppe, Kroger, Barney’s DSW, Sephora, CVS, American Eagle, Dick’s Sporting Goods, and Walgreens have all stocked shelves with CBD products.
The best part -- we could potentially see even more retailers jump on the bandwagon in 2020.
One of The Top Beneficiaries Could Be US Lithium Corp. (LITH)
As of January 21st, 2020, LITH has entered the CBD market. As it transitions from minerals to cannabinoids, its Board of Directors and shareholders approved changing the name of the corporation from U.S. Lithium Corp. to BioELife Corp in the next 30 days. The name change will better reflect the Company’s new strategic focus on the rapidly growing CBD market.
US Lithium Corp.’s new strategic direction was created by successful pharmaceutical entrepreneurs dedicated to using nature’s resources to fight pain and infection while reducing the dependency on opioids and their terrible side effects. It is now uniquely positioned to capitalize on the emerging Cannabinoid market that is expected to reach $20 billion by 2025.
The Company has also created a ‘seed to shelf’ value-added product development and marketing organization with direct contracts for raw materials, scientific formulation, manufacturing, and distribution of medically focused Cannabinoid products.
Catalyst No. 1 -- Strong Buy Technical Indicators Triggered On Bar Chart
Short Term Indicators 20 Day Moving Average BUY
20 - 50 Day MACD Oscillator BUY
20 - 100 Day MACD Oscillator BUY
20 - 200 Day MACD Oscillator BUY
50-Day Moving Average BUY
50-100 Day MACD Oscillator BUY
50-150 Day MACD Oscillator BUY
50-200 Day MACD Oscillator BUY
100 Day Moving Average BUY
150 Day Moving Average BUY
200 Day Moving Average BUY
100-200 Day MACD Oscillator BUY
No. 2 Catalyst That Could Potentially Create Sizable Awareness Is Its CBD Transition
Read The Full News Release That Recently Came Out Below
PRESS RELEASE
US Lithium Corp. Announces It Has Approved Name Change To BioELife Corp. To Reflect New Direction
Published: Feb. 5, 2020
HENDERSON, Nev., Feb. 05, 2020 / GLOBE NEWSWIRE / US Lithium Corp is pleased to announce that its Board of Directors and shareholders have approved an amendment to the Articles of Incorporation changing the name of the corporation from U.S. Lithium Corp. to BioELife Corp. The name change will better reflect the Company’s new strategic focus on the rapidly growing CBD market. The Company expects this action will become effective within the next 30 days. The Company will also be launching a new website and seek a new trading symbol for its common stock immediately after the name change becomes effective.
“BioELife reflects the Company’s new direction into helping improve individual lives through non-addictive remedies for stress and pain relief as well as other medical purposes,” stated Gregory Rotelli, Chairman of the Board and President of LITH. Mr. Rotelli further stated, “We’re positioning our Company as ’Nature’s Bio Equivalent’ with a ‘seed to shelf’ philosophy. Our raw materials are sourced directly from our partner farms in America’s heartland which grow only the best quality CBD strains for use in all our formulations. Throughout our farming and GMP manufacturing process, our products are made using the purest and most potent ingredients available and are backed by clinical data and independent laboratory testing.”
BioELife currently partners with well-known farmers, certified contract manufacturers and key distributors to produce and distribute exceptional products at the lowest possible cost. Positive testimonials from BioELife clients and patients continue to substantiate the Company’s objective to provide products that perform better than any currently on the market and often better than prescription medications. The Company has already expanded manufacturing and distribution channels in these first few weeks since entering the CBD industry.
No. 3 Catalyst Are The Company’s Key Products And Deals In The CBD Industry
PRESS RELEASE
US Lithium Corp. (BioELife Corp.) Releases ChiroRub 2000, the Next Generation CBD Pain Cream
Published: Feb. 12, 2020
HENDERSON, Nev., Feb. 12, 2020 / GLOBE NEWSWIRE / US Lithium Corp, soon to be renamed BioELife Corp., is pleased to announce that it has completed production and began shipping its latest pain cream, ChiroRub 2000. The proprietary formulation, containing 2,000 mg of CBD, has been doctor and patient tested and is one of the most effective pain relief creams currently available on the market today. ChiroRub 2000 was developed in conjunction with leading physicians, chiropractors, and medical professionals who evaluated and validated the product’s efficacy throughout several developmental phases.
Matthew DeNomme, principal with CBDNext, stated “We are proud to be a master distributor of ChiroRub 2000. After extensive research, we’re confident that ChiroRub 2000 is the most effective pain cream on the market and is priced at an exceptional value for our customers.”
“ChiroRub 2000 is one of our first product launches and has been validated through a network of medical professionals. It is one step toward our goal of improving people’s lives through the use of non-addictive remedies that provide relief and are cost effective,” stated Gregory Rotelli, Chairman of the Board and President of LITH. Mr. Rotelli also stated, “This further reflects our continuing commitment to product development in conjunction with our medical professional advisors and customers."
BioELife partners with well-known farmers, certified contract manufacturers and key distributors to produce and distribute exceptional products at the lowest possible cost. Current products now include CBD Gummies, high quality hemp pre-rolls, and bulk premium flower in addition to ChiroRub 2000. Several of these products are being marketed by medical networks in various combination packages to maximize patient benefits and efficacy. Positive testimonials continue to substantiate the Company’s products’ effectiveness.
PRESS RELEASE
US Lithium Corp. Wins Manufacturing & Distribution Contract from International Healthcare Network
Published: Jan. 30, 2020
HENDERSON, NV, Jan. 30, 2020 / GLOBE NEWSWIRE / US Lithium Corp is pleased to announce that its CBD manufacturing business has been awarded an exclusive purchase and distribution agreement by International Healthcare Network (“IHN”) for at least four of its products. One much anticipated product is a highly concentrated topical pain cream developed in conjunction with leading chiropractors across the country.
“After extensive patient testing, our products were chosen due to their effectiveness and value. We are proud to have been selected by IHN and look forward to working with them on the marketing and distribution of our CBD-based products,” stated Gregory Rotelli, Chairman of the Board of LITH.
“We’re excited to partner with Greg and his team to supply effective pain relief products across our network. Medical professionals and patients alike quickly recognized the quality of the products during our evaluation trials,” stated Dr. Donald Cenk, a principal of IHN and one of the nation’s leading chiropractors.
This multiyear agreement is an example of the Company’s focus on securing large distributor arrangements with proven sales and medical organizations. Initial sales and product fulfillment efforts will begin this month and will include significant mass media advertising across a multitude of channels.
PRESS RELEASE
US Lithium Corp. Enters CBD Industry Through Strategic Asset Acquisition
Published: Jan. 21, 2020
Effective January 20, 2020, it has acquired four cannabinoid related contracts between Hemp Cloud 9 and four unrelated parties in exchange for 4.7M shares of LITH stock.
Through this acquisition the Company now has contractual relationships with well-known farmers for raw material acquisition, certified contract manufacturers for production, and distribution partners to sell exceptional products at the lowest possible cost to both the CBD and medical industry. The Company will control its products from ’seed to shelf’ without the need for expensive infrastructure and operating overhead. Instead, the Company will be able to dedicate its resources primarily to product development and sales.
“This acquisition positions our company as a contract manufacturer and supplier in the high growth cannabinoid industry. Going forward our focus will be on helping improve the lives of individuals while maximizing shareholder value,” stated Gregory Rotelli, Chairman of the Board.
The collective market for CBD sales is expected to exceed $20 billion in the United States by 2024, according to BDS Analytics and ArcView Market Research. The Company now has the key farming, manufacturing, and distribution agreements in place to become a major force in this exciting new growth industry. Announcements regarding initial products and distribution channels will be forthcoming over the coming weeks.
No. 4 Catalyst: CBD Is Quickly Becoming A Massive Market With Sizable Demand
The CBD industry saw a 700% increase in demand in 2019, according to Stephanie Wissink, Managing Director of Consumer Research at Jefferies.
Better, in the U.S. alone, analysts at Nielsen project CBD sales of $6 billion by 2025.
“From over-the-counter medications, to cosmetics, pet care and even products throughout the traditional food and beverage space, the future potential of hemp-based CBD could impact billions in CPG sales across categories.”
“As legal restrictions are loosened, the process of bringing a hemp CBD product to market, including the leveraging of mainstream distribution channels, could soon mirror that of other CPG (consumer packaged goods) products,” they added.
Conclusion For This New Potential Winner
With plenty of CBD demand from consumers, retailers, and the global community, LITH could potentially witness sizable growth moving forward.
Based on LITH’s shift to CBD, along with attractive new deals and products firmly in place, LITH is potentially positioning itself for monster growth down the road.
Stay tuned for more updates...
Regards,
Dan Davis
Editor
StockStreetWire
